Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China

Author: Vandana Singh | June 03, 2021 08:18am

The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC:IVBXF) and Eli Lilly And Co's (NYSE:LLY) Tyvyt (sintilimab injection) in non-small cell lung cancer (NSCLC).
The approval is for expanded use of Tyvyt in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC).
It is the third NMPA-approved indication of Tyvyt, following the approval in December 2018 for relapsed or refractory classical Hodgkin's lymphoma, and the approval in February 2021 for the first-line treatment of non-squamous non-small cell lung cancer.
Related content: Benzinga's Full FDA Calendar.
Price Action: LLY shares closed at $199.13 on Wednesday.